- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medivir AB ser. B (MVR0)
Medivir AB ser. B stock price live, this page displays ST MEDIVIR stock exchange data. View the MEDIVIR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Medivir AB ser. B real time stock price chart below.
What Is the Medivir AB ser. B Stock Price Today?
The Medivir AB ser. B stock price today is 0.14.
What Is the Stock Symbol for Medivir AB ser. B?
The stock symbol for Medivir AB ser. B is ""MEDIVIR.""
What Stock Exchange Does Medivir AB ser. B Trade On?
Medivir AB ser. B is listed and trades on the Stockholm stock exchange.
Is Medivir AB ser. B a Good Stock to Buy?
Determining whether Medivir AB ser. B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MEDIVIR quote. (ISIN: SE0020181014)
What Is the Medivir AB ser. B Stock Price Today?
The Medivir AB ser. B stock price today is 0.14.
What Is the Stock Symbol for Medivir AB ser. B?
The stock symbol for Medivir AB ser. B is ""MEDIVIR.""
What Stock Exchange Does Medivir AB ser. B Trade On?
Medivir AB ser. B is listed and trades on the Stockholm stock exchange.
Is Medivir AB ser. B a Good Stock to Buy?
Determining whether Medivir AB ser. B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MEDIVIR quote. (ISIN: SE0020181014)
0.14
-0.03(-15.91%)
Delayed Data·
Fair Value
An estimate of a Medivir AB ser. B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.14
0.14
52 wk Range
0.07
0.34
MVR0 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MVR0 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Medivir AB ser. B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.140.14
52 wk Range
0.070.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
MVR0 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Medivir AB ser. B's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
21.50
Upside
+15,257.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Medivir reports progress in liver cancer study
- Investing.com
- Medivir reports progress in liver cancer study
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Medivir AB ser. B Company Profile
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Compare MVR0 to Peers and Sector
Metrics to compare | MVR0 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMVR0PeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −9.6x | −0.5x | |
PEG Ratio | −0.06 | −0.20 | 0.00 | |
Price/Book | 2.0x | 6.6x | 2.6x | |
Price / LTM Sales | 56.1x | 42.3x | 3.3x | |
Upside (Analyst Target) | 250.7% | 10.5% | 43.5% | |
Fair Value Upside | Unlock | 6.5% | 6.9% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 21.50
(+15,257.14% Upside)
Earnings
Latest Release
Apr 29, 2025
EPS / Forecast
-0.12 / --
Revenue / Forecast
600.00K / --
FAQ
What Stock Exchange Does Medivir AB ser. B Trade On?
Medivir AB ser. B is listed and trades on the Frankfurt Stock Exchange stock exchange.
What Is the Stock Symbol for Medivir AB ser. B?
The stock symbol for Medivir AB ser. B is "MVR0."
What Is the Medivir AB ser. B Market Cap?
As of today, Medivir AB ser. B market cap is 20.10M.
What Is Medivir AB ser. B's Earnings Per Share (TTM)?
The Medivir AB ser. B EPS (TTM) is -0.97.
From a Technical Analysis Perspective, Is MVR0 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Medivir AB ser. B Stock Split?
Medivir AB ser. B has split 0 times.
How Many Employees Does Medivir AB ser. B Have?
Medivir AB ser. B has 10 employees.
What is the current trading status of Medivir AB ser. B (MVR0)?
As of 07 Aug 2025, Medivir AB ser. B (MVR0) is trading at a price of 0.14, with a previous close of 0.16. The stock has fluctuated within a day range of 0.14 to 0.14, while its 52-week range spans from 0.07 to 0.34.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.